Curis Provides Second Quarter 2024 Financial and Operating Update

EC Grants ODD to emavusertib in PCNSL Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 1, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2024. Operational Highlights TakeAim Lymphoma In July 2024, emavusertib was granted Orphan Drug Designation (OD ...